

Luqa, Stratpharma extent China collaboration

24 April 2013 | News | By BioSpectrum Bureau



Singapore: China focused company, Luqa Pharmaceuticals has announced its decision to extend its collaboration with Swiss company Stratpharma in China past 2020. Both the companies will focus on the fields of cosmetic dermatology, plastic surgery, burns, wounds and scar management in the country.

The collaboration will encompass an expanded range of innovative medical devices in the areas of cosmetic dermatology, plastic surgery, burns, wounds and scar management as well as preferential rights to Stratpharma's new products under development.

As per the extended collaboration agreement, Luqa Pharmaceuticals will register and commercialize Stratpharma's innovative pipeline in China, rolling out four new products over the next three years.

"We are delighted with the progress of our collaboration with Stratpharma following the successful launch of Strataderm in China. Over the last years, Stratpharma and Luqa have formed a strong and close working relationship. We are excited to

extend our collaboration to develop and commercialize innovative new treatments in order to further our contribution to enhance the quality of life of China's population," said Robert Braithwaite, CEO of Luqa Pharmaceuticals at the announcement.